The review concluded that erlotinib and gefitinib were suitable for treatment of platinum pre-treated non-small cell lung cancer, but may not be useful in ovarian cancer. Potential differences across the trials, uncertain quality of the included trials and the unspecified form of pooling mean that caution is warranted when interpreting the authors' conclusions.
To investigate whether erlotinib or gefitinib have efficacy in patients with relapsed pre-treated non-small cell lung cancer and ovarian cancer.
Searching
MEDLINE and EMBASE were searched to February 2011 for articles published in English. Search terms were reported Reference lists of included articles were searched.
Study selection
Clinical trials of erlotinib or gefitinib (alone or in combination) for the treatment of cancer in patients who had previously received platinum-based chemotherapy were eligible for inclusion. Trials of chemotherapy-naïve patients or first-line therapy were excluded. Maintenance therapy for non-relapsed/non-progressed platinum pre-treated patients were excluded.
The included trials studied: erlotinib (100 to 150mg/day) alone or in combination with bevacizumab or pemetrexed for non-small cell lung cancer and alone or with carboplatin and bevacizumab for ovarian cancer; gefitinib (250 to 500mg/day) alone or in combination with vinorelbine, celecoxib, rofecoxib or cetuximab for non-small cell lung cancer and alone or with tamoxifen, paclitaxel and carboplatin for ovarian cancer. The platinum status for most of the patients recruited to the trials was unknown. Some trials specified some or all patients as platinum refractory or resistant. Some trials also included platinum sensitive patients. The proportion of Asian patients, where reported, comprised 0% to 100%. The reported outcomes included various response and survival measures. Some trials reported the epidermal growth factor receptor (EGFR) status of patients and the resulting proportion of EGFR responders.
